Journal
/
/
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
JoVE Journal
Bioengineering
A subscription to JoVE is required to view this content.  Sign in or start your free trial.
JoVE Journal Bioengineering
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
DOI:

08:03 min

October 20, 2022

, , , , , , , ,

Chapters

  • 00:04Introduction
  • 00:53Plate Coating
  • 01:58Seeding of Human iPSC‐Derived Cardiomyocytes into Flexible 96‐Well Plates (Day 0)
  • 02:56Medium Exchange of Flexible 96‐Well Plates (Day 1)
  • 03:53Final Medium Exchange Before Compound Addition (Day 5–7)
  • 04:21Compound Addition and Data Recording (Day 5–7)
  • 05:47Results: Contractility Assessment, Base Impedance, and EFP Recordings of Human iPSC‐Derived Cardiomyocytes After Drug Treatment
  • 07:35Conclusion

Summary

Automatic Translation

The analysis of changes in contractile function and cellular integrity of human iPSC-derived cardiomyocytes is of immense importance for nonclinical drug development. A hybrid 96-well cell analysis system addresses both parameters in a real-time and physiological manner for reliable, human-relevant results, necessary for a safe transition into clinical stages.

Related Videos

Read Article